17.85 0.00 (0.00%)
After hours: 4:53PM EDT
|Bid||17.80 x 3200|
|Ask||17.84 x 4000|
|Day's Range||17.62 - 17.95|
|52 Week Range||16.63 - 39.59|
|Beta (3Y Monthly)||2.10|
|PE Ratio (TTM)||38.80|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.47|
A federal judge dealing a blow to the Trump Administration by striking down a new rule that would have forced pharma companies to include the wholesale prices of their drugs in TV ads. Yahoo Finance's Seana Smith and Alexis Keenan discuss.
Pharmaceutical stocks have been under pressure for the past few trading days, but one Wall Street analyst said the worst is yet to come for a handful of specialty drugmakers. The Analyst Morgan Stanley ...
Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company announced today that is has signed a long term lease agreement at the Har-Hotzvim Hi-Tech Park in Jerusalem for the establishment of a new sterile production plant for GA Depot injectable products. The ~50,000 square foot plant was previously part of Omrix Biopharmaceuticals, Inc., a Johnson & Johnson Company, and was an FDA-approved facility. The new leased area will be used for commissioning a commercial scale production facility for GA Depot and is a scale-up to the current Israeli Ministry of Health (MOH) GMP approved facility the Company operates to supply the ongoing clinical trials (Phase II, III).
Walgreens Boots Alliance Inc said on Thursday it expanded its partnership with Kaleo Inc to include the company's epinephrine auto-injectors for infants and toddlers in its pharmacies amid a national shortage of the emergency allergy shots. Walgreens already offers two other doses of Kaleo's emergency allergy shots, Auvi-Q, under a partnership that the drugstore chain entered with the company in September last year.
Pfizer stock has run sideways this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat. But the question remains: Is Pfizer stock a buy right now?
(Bloomberg) -- A persistent shortage of Mylan NV’s EpiPen anti-allergy injectors is forcing patients and pharmacists to go to great lengths to get their hands on the lifesaving device.EpiPens, which can help stop a severe or life-threatening allergic reaction, have been hard to get since at least May 2018, when the Food and Drug Administration said the device was in short supply. While other options are available, including an identical lower-priced version of the device from Mylan, consumers have also struggled to secure alternatives thanks to uneven distribution, the reluctance of insurers to pay for similar treatments and uneasiness with unfamiliar products.Even patients who live near numerous pharmacies have been scrambling. Boston resident Justin Klaassen said he drove 45 minutes outside the city earlier this year to find EpiPens for his 7-year-old daughter. Everywhere he called within 10 miles of Boston was out of stock of the device, which carries a list price of more than $600 for a two-pack but has been scarce because of manufacturing problems.“My family has enough money to buy one with insurance, you know, and even two because you want one at school and you want one at home,” Klaassen said. “But there are families out there who can’t even afford one, and then you have the problem finding them.”EpiPens can be especially difficult to track down at the start of a new school year, when sales tend to peak. Teachers and staff in school districts across the U.S. have been trained to use the devices, while few have been shown how to use rivals like Adrenaclick and Auvi-Q. Some parents say that they worry that the few moments needed to get familiar with a new injector could be costly in an emergency.Pharmacists are racing to keep EpiPens on their shelves, scooping up fresh supply whenever they can. Ashley Seyfarth, the owner of New Mexico pharmacy Kare Drug, said she “plays the back-order game,” ordering from her wholesaler as soon as a shipment comes in regardless of whether she has prescriptions that need immediate filling.Steps taken by U.S. regulators in recent weeks suggest that they expect the deficit of EpiPen brand injectors to linger, meaning more headaches likely await parents of students returning to school next month. In June, the FDA said expiration dates for some devices would be extended by four months.Mylan has been providing information about EpiPen production and distribution shortages to the FDA on a weekly basis, said agency spokesman Nathan Arnold. The FDA can’t say when the shortage will end, he said.“The FDA looks at drug shortages on a national scale,” Arnold said. “There may be local shortages in any given area of the United States even when there are not national shortages."Mylan shares declined as much as 5.4% on Wednesday, the largest intraday decline in more than a month. So far this year, the drugmaker’s stock price has fallen by 32%.The current problems finding EpiPens can be traced back to September 2017, when Pfizer Inc.’s Meridian Medical Technologies division, which makes them for Mylan, received a warning from the FDA after allegedly failing to investigate hundreds of complaints about faulty devices.Pfizer spokeswoman Kim Bencker said the company is also frustrated by the unsteady supply and that EpiPens involve a “highly complex and technical” manufacturing process.“Despite our significant efforts, we do anticipate further supply shortages over the coming months,” Bencker said. “Product is routinely shipping, and we are committed to permanently resolving this availability issue as quickly as possible.”Mylan spokeswoman Lauren Kashtan said the company is sending shipments as soon as it receives the product from Meridian and encourages people to call customer relations for assistance in locating alternative pharmacies. The generic injector made by Mylan isn’t offically in shortage, according to the FDA.Production problems have also vexed makers of competing injectors. Amneal Pharmaceuticals Inc. lowered its earnings guidance for 2019 on Wednesday due in part to uncertainty about supplies of its generic version of Adrenaclick.Shares of the company declined as much as 37%, the steepest intraday decline since May 2010. Amneal’s product is also manufactured by Pfizer’s Meridian unit, Amneal spokesman David Belian said.Inventory IssuesPharmacists say that nailing down when they can get more EpiPens has been difficult. Carter High, owner of Best Value Rhome Pharmacy in Texas, said his wholesaler has pushed back the date when more injectors would be available several times.“As a parent, I look at that and think, God I wish I could help them,” High said. “I can’t. There’s nothing to give them because I just can’t get it.”High said he has also had difficulty obtaining Mylan’s generic EpiPens. At times, he said he gave patients epinephrine, the drug delivered by a shot from Mylan’s device, the “old-school way,” with a syringe. He said he tells patients to keep expired EpiPens because it’s “better to have something than nothing.”In the meantime, brand-name EpiPen prescriptions have swooned. After peaking at more than 580,000 in August 2016, there were just 27,000 in May 2019, according to data compiled by Bloomberg Intelligence.Going without an EpiPen can be dangerous for patients like Ashley Spencer, 29. She was eating a strawberry when she went into anaphylaxis on June 23. Her skin was bright red and itchy. Her throat was closing.Spencer, who suffers from a rare autoimmune disease, didn’t have an EpiPen. She’d been waiting for a refill for more than a week when her body developed the new allergy.“I can’t go a week and a half without it because my disease also can cause me to go into anaphylaxis at any time,” Spencer said. EpiPens “are crucial to my life.”“As a parent, I look at that and think, God I wish I could help them...There’s nothing to give them because I just can’t get it.”Insurance companies have sometimes balked at paying for pricier alternatives. High, the Texas pharmacist, said wholesalers “have plenty of Auvi-Q, but at $5,000 a whack, I can’t even get insurance to pay for that.” While some large pharmacy chains have struck agreements with EpiPen competitors to try to alleviate the shortage and reduce patients costs, others have struggled to get insurers to pay for alternatives.“Though there are other things out there, we can’t use them even if we can get our hands on them,” said Seyfarth, the pharmacist in New Mexico.Additionally, a new generic made by Teva Pharmaceutical Industries Ltd. has been difficult to track down, pharmacists say. “I’ve never actually seen Teva’s product in the marketplace,” said Hamilton, New Jersey, pharmacist Eklavya Lalwani.In an earnings call in May, Teva Chief Executive Officer Kare Schultz said the company is “ramping up the volumes” and is distributing its injector to Anda Inc., a supplier the drugmaker owns. “Any pharmacy who needs EpiPen can just call Anda, and they will get it within 24 hours,” Schultz said in May.Teva spokeswoman Kelley Dougherty said the company has no backorders for the product, but both High and Lalwani said it was indicated as out of stock in Anda’s ordering system on July 8.Elsewhere, Sandoz, a division of Swiss drug giant Novartis AG, said on Tuesday that Symjepi epinephrine injections, previously only given in hospitals and clinics, will now be available at pharmacies.Even when insurance covers another brand, some parents like Klaassen, in Boston, have trained their family and friends on Mylan’s device and don’t want to switch. Others such as Erin Malawer, who lives near Washington, switched her 14-year-old son to Auvi-Q but still tries to find at least one EpiPen, because she fears that his friends or teachers might not recognize an alternative device in an emergency.“If you’re looking for an EpiPen, blue and orange tube, and it’s not there, you’re wasting precious seconds that could save a life,” Malawer said.(Updates with Amneal Pharmaceuticals comment in the 17th paragraph.)To contact the author of this story: Myah Ward in New York at email@example.comTo contact the editor responsible for this story: Drew Armstrong at firstname.lastname@example.org, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
It looks like there is no end is sight to the EpiPen shortage and Mylan (NASDAQ:MYL) stock is taking a beating Wednesday on the news.Source: Shutterstock Recent statements from the company note that it continues to expect the EpiPen shortage to continue. This is leaving many parents without a way to purchase the medicine as they prepare for the next school season to begin.The reason behind the EpiPen shortage is that the company had production issues back in 2017. Following these problems, the U.S. Food & Drug Administration (FDA) announced that there was a shortage of the devices in the following year. The FDA still has EpiPens listed as in short supply.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo what exactly can parents do to get around the EpiPen shortage? There's always the option of going with the generic version of the drug, which is also made by Mylan. The FDA does not list this one as being limited in supply.Another option that parents may want to consider are rival products. This includes those made by Teva Pharmaceutical (NYSE:TEVA) or Novartis (NYSE:NVS). However, there are concerns about the difference in using these devices and them not being as recognizable as normal EpiPens, reports Bloomberg. * 7 Retail Stocks to Buy for the Second Half of 2019 The Novartis option may be the best one for parents on a budget. The company is selling a two-pack of adult dosage syringes for $250. This is below the $300 price for a comparable pack of Mylan's generic version, Reuters notes.MYL stock was down 3% as of noon Wednesday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy on College Students' Radars * 7 Retail Stocks to Buy for the Second Half of 2019 * The S&P 500's 5 Best Highest-Yielding Dividend Stocks As of this writing, William White did not hold a position in any of the aforementioned securities.The post EpiPen Shortage: Mylan (MYL) Stock Falls on Continued Scarce Supply appeared first on InvestorPlace.
Novartis said earlier this week it would make a generic EpiPen to fill the void of Mylan's shortage.
Amneal Pharmaceuticals Inc on Wednesday cut its 2019 core earnings forecast, citing the uncertain supply of epinephrine auto-injectors amid a global shortage of the emergency allergy shots, including Mylan NV's EpiPen. Amneal now expects full-year adjusted earnings before interest, tax, depreciation and amortization in the range $425 million to $475 million, compared with its previous forecast of $600 million to $650 million. The supply disruption has plagued Amneal for over a year, and the company saw its 2018 combined generics net revenue fall 2.6%, hurt mainly by lower sales of its epinephrine auto-injector.
Novartis AG said on Tuesday it would make its generic pre-filled epinephrine shots immediately available in local pharmacies across the United States, as a shortage of Mylan NV's EpiPen emergency allergy treatment drags on due to manufacturing problems. Novartis' Sandoz unit launched the Symjepi epinephrine shots for use in hospitals in January and had said it would make the treatment available in pharmacies in a phased manner.
A unit of Novartis AG said on Tuesday it would make partner Adamis Pharmaceuticals Corp's emergency allergy shots immediately available in local pharmacies across the United States, amid a shortage of Mylan NV's rival product, EpiPen. The Sandoz unit of Novartis launched Symjepi for use in hospitals in January and had said it would make the treatment available in pharmacies in a phased manner. Mylan dominates the market for emergency allergy shots with EpiPen, an auto-injector that delivers a dose of epinephrine in the event of severe allergic reactions to a number of triggers, including bee stings or peanuts.
HERTFORDSHIRE, England and PITTSBURGH and SYDNEY , July 8, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) and medical device manufacturer Atomo Diagnostics today announced ...
The company did not disclose the breakdown of the voting, but as one investor said "it's clear there is support among investors for strengthening Mylan's policy regarding clawbacks."
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), a leading specialty pharmaceutical company with a strong North American commercial platform, announces that Adele M. Gulfo has joined the Company's Board of Directors, further enhancing the Board’s commercial and business development expertise. Ken d’Entremont, Chief Executive Officer of Medexus, commented, “We are thrilled to add Adele to our Board of Directors.
Shares of drug makers were getting a nice boost in premarket trading Tuesday, after AbbVie Inc.'s deal to buy Allergan PLC for a 45% premium. The SPDR S&P Pharmaceuticals ETF rallied 2.2% ahead of the open. Besides the 31% jump in Allergan's stock, among other shares seeing nice gains in the premarket, Mylan N.V. rose 2.7%, Endo International PLC climbed 4.5%, Theravance Biopharma Inc. hiked up 4.2%, Mallinckrodt PLC tacked on 2.7% and Perrigo Co. PLC gained 2.2%. Meanwhile, Medicines Co.'s stock shed 4.6%, after the company announced late Monday the public offering of $150 million worth of common stock. The pharmaceuticals ETF has lost 7.7% over the past three months through Monday, while the S&P 500 has gained 5.3%.
Mylan NV NASDAQ/NGS:MYLView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for MYL with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold MYL had net inflows of $2.69 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, June 14, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced the expansion of the companies' current development and commercialization agreement for nebulized revefenacin to include China and certain adjacent territories. Revefenacin, marketed as YUPELRI® in the U.S., is a long-acting muscarinic antagonist (LAMA), which is the first and only once-daily, nebulized bronchodilator approved for the treatment of chronic obstructive pulmonary disease (COPD) in the U.S.
Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays' has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * Organigram (OGI) Growth Experiment Hits Earnings - Long-Term Narrative Remains Solid * Can Curaleaf Stock Keep Going After This Week’s 22% Pop? This Analyst Says Yes * This Analyst Doesn't See a Comeback in Netflix (NFLX) Stock Any Time Soon * There's Light at the End of the Tunnel for Canopy Growth (CGC) Stock, Analyst Says